Status:
COMPLETED
Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer
Lead Sponsor:
Uppsala University
Collaborating Sponsors:
Karolinska Institutet
Cyto Pulse Sciences, Inc.
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study will assess the feasibility and safety of vaccination with increasing doses of xenogenic DNA administered intradermally in combination with electroporation in patients with relapse of prost...
Eligibility Criteria
Inclusion
- Male patients. Age \>18 years.
- HLA-A\*0201 positive.
- Histologically confirmed prostate cancer.
- Minimum two (2) and maximum four (4) years after treatment with curative or salvage radiotherapy.
- Serum testosterone within normal range.
- Increasing PSA from a previous reference value on two (2) consecutive occasions at least one month apart and with a minimum of 2 ng/mL above nadir.
- PSA doubling time is one (1) year or less.
- No evidence of metastatic prostate cancer.
- Karnofsky performance status ≥ 80.
- Adequate organ function:
- AST and ALT ≤ 2.0 x upper limit of normal (ULN); total serum bilirubin ≤ 1.5 x ULN
- Calcium ≤ 2.6 mmol/L, serum creatinine ≤ 1.5 x ULN
- Hb ≥ 100 g/L; absolute leukocyte count ≥ 3.0 x 109 /L; platelets ≥100 x 109 /L
- Life expectancy ≥ 12 months.
- Swedish or English speaking subjects only.
- Written informed consent (subjects must be capable of providing their own informed consent).
Exclusion
- Previous ablation of testis.
- Radiologic evidence of metastatic disease.
- Prior chemotherapy or investigational therapy/agents within 4 weeks.
- Active bacterial, viral or fungal infection.
- Carrier of HIV, HBV, or HCV.
- Immunosuppressed (post splenectomy, post stem cell transplantation) or on immunosuppressive therapy other than inhaled or replacement corticosteroids.
- Any other major illness or peripheral blood vein status that, in the investigator's judgement, will substantially increase the risk associated with sampling or participation in this study.
- Subjects with cardiac demand pacemakers.
- Any reason why, in the opinion of the investigator, the patient should not participate.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00859729
Start Date
December 1 2008
End Date
November 1 2011
Last Update
March 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Oncology, University Hospital Uppsala
Uppsala, Sweden, 751 85